Dr. Driver-Dunckley teaches medical students at the Mayo Medical school and serves as a mentor for students, residents, and junior faculty. She has developed and led several Mayo Clinic CME courses and conferences in Neurology and Movement Disorders. She is the principal investigator or a co-investigator at Mayo Clinic in multiple clinical trials and collaborates with researchers at Arizona State University (ASU) and Banner Sun Health Research Institute.

Her primary research focus is in Parkinson's disease, Progressive Supranuclear Palsy, Essential Tremor, and Restless Legs Syndrome. The research of Erika D. Driver-Dunckley, M.D., focuses on identifying the causes of, and improving the treatments for, Parkinson's disease, atypical parkinsonisms, essential tremor, dystonia, and other movement disorders. These studies involve epigenetics and the pathology of Parkinson's disease and are conducted in collaboration with the Arizona Parkinson's Disease Consortium and the Arizona Study of Aging and Neurodegenerative Disorders. Dr. Driver-Dunckley's research has led to several advances in patient care. Dr. Driver-Dunckley continues to be a leader in testing new therapies for patients.

Dr. Reiman is Executive Director of the Banner Alzheimer’s Institute, Chief Executive Officer of Banner Research, Professor of Psychiatry at the University of Arizona, University Professor of Neuroscience at Arizona State University, Clinical Director of Neurogenomics at the Translational Genomics Research Institute (TGen), and Director of the Arizona Alzheimer’s Consortium. 

He received his undergraduate and medical education at Duke University and his Psychiatry Residency Training at Duke and Washington University, and launched his career in brain imaging research under the mentorship of Marcus Raichle at Washington University in St. Louis. He has played leadership roles in brain imaging, and genomics research, the unusually early detection and tracking of Alzheimer’s disease (AD), and the accelerated evaluation of Alzheimer’s prevention therapies. He has also sought to advance new models of biomedical research collaboration and dementia care. 

Dr. Reiman and his Banner Alzheimer’s Institute colleagues established the Alzheimer’s Prevention Initiative (API) to launch a new era in Alzheimer’s prevention research. API includes public-private partnerships, prevention trials and biomarker development programs in cognitively unimpaired persons at high genetic and/or biomarker risk for AD, unusually large registries and innovative programs to support enrollment in these and other studies, precedent-setting trial data and biological sample sharing agreements, and other efforts to help find and support the approval, affordability and availability of prevention therapies as soon as possible. 

Dr. Reiman is an author of more than 500 publications, a principal investigator of seven current NIH grants, and a member of the National Advisory Council on Aging (NIA Council). He is a recipient of the Potamkin Prize for his pioneering contributions to the study of preclinical AD and the accelerated evaluation of AD prevention therapies.